Onkológia S5/2024
Efficacy and tolerance of ARTA treatment in a patient with metastatic hormone-sensitive prostate cancer
Introduction: The treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has seen significant advancements in recent years. Androgen receptor-targeted agents (ARTA), such as abiraterone acetate, enzalutamide, apalutamide, and darolutamide, in combination with androgen deprivation therapy (ADT) and, in certain cases, docetaxel, have significantly improved survival in patients with mHSPC. Studies such as LATITUDE, PEACE-1, ARCHES, TITAN, and ARASENS have demonstrated the efficacy of ARTA agents, showing significant improvements in overall survival (OS) and radiographic progression-free survival (rPFS), with an acceptable safety profile. Case report: In our case report, we present an 84-year-old patient with mHSPC who achieved two years of progression-free survival and good quality of life with ARTA therapy. The substitution of one ARTA agent for another did not affect the efficacy or tolerance of the treatment. Conclusion: Both abiraterone acetate and enzalutamide demonstrated high efficacy and low toxicity in a patient with mHSPC.
Keywords: hormone-sensitive prostate cancer, abiraterone acetate, enzalutamide, apalutamide, darolutamide, rheumatoid arthritis
